Tamoxifen, HER2, and Endoxifen: The Role of CYP2D6 as a Predictor of Tamoxifen Resistance in ER+/HER2+Breast Cancer

被引：0
|
作者：
Goetz, M. P.
Reinicke, K. E.
Reid, J. M.
Suman, V. J.
Kuffel, M. J.
Safgren, S. L.
Buhrow, S. A.
Reynolds, C. A.
Jenkins, R. B.
Hawse, J. R.
Perez, E. A.
Ingle, J. N.
Ames, M. M.
机构：
[1] Mayo Clin, Rochester, MN USA
[2] Mayo Clin, Jacksonville, FL 32224 USA
来源：
CANCER RESEARCH | 2009年 / 69卷 / 24期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：594S / 594S
页数：1
相关论文
共 50 条
  • [21] Optimized CYP2D6 phenotype assignment for plasma endoxifen prediction in breast cancer patients treated with tamoxifen
    Schroth, Werner
    Winter, Stefan
    Eichelbaum, Michel
    Muerdter, Thomas
    Schwab, Matthias
    Brauch, Hiltrud
    CANCER RESEARCH, 2017, 77
  • [22] CYP2D6 and Endoxifen in Tamoxifen Therapy: A Tribute to David A. Flockhart
    Skaar, Todd C.
    Desta, Zeruesenay
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2018, 103 (05) : 755 - 757
  • [23] Therapeutic targeting of Rac GTPases in ER+ and HER2+breast cancer
    Hampsch, R. A.
    Shee, K.
    Miller, T. W.
    CANCER RESEARCH, 2016, 76
  • [24] Re: CYP2D6 Genotyping and the Use of Tamoxifen in Breast Cancer
    Province, Michael A.
    Klein, Teri E.
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2014, 106 (02):
  • [25] CYP2D6 GENOTYPING TO GUIDE USE OF TAMOXIFEN IN BREAST CANCER
    Irvin, William J., Jr.
    Weck, Karen E.
    Walko, Christine M.
    Ibrahim, Joseph G.
    Chiu, Wing. K.
    Dees, E. Claire
    Ogburn, Evan T.
    Desta, Zeruesenay
    Flockhart, David A.
    McLeod, Howard L.
    Evans, James P.
    Carey, Lisa A.
    CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2011, 49 : S88 - S88
  • [26] The effect of rs5758550 on CYP2D6☆2 phenotype and formation of endoxifen in breast cancer patients using tamoxifen
    Sanchez-Spitman, Anabel B.
    Moes, Dirk-Jan A. R.
    Gelderblom, Hans
    Dezentje, Vincent O.
    Swen, Jesse J.
    Guchelaar, Henk-Jan
    PHARMACOGENOMICS, 2017, 18 (12) : 1125 - 1132
  • [27] Tamoxifen Use in Postmenopausal Breast Cancer: CYP2D6 Matters
    Brauch, Hiltrud
    Schroth, Werner
    Goetz, Matthew P.
    Muerdter, Thomas E.
    Winter, Stefan
    Ingle, James N.
    Schwab, Matthias
    Eichelbaum, Michel
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (02) : 176 - 180
  • [28] Role of endocrine therapy in ER+/HER2(+) breast cancers
    Webber, Victoria L.
    Dixon, J. Michael
    BREAST CANCER MANAGEMENT, 2014, 3 (01) : 103 - 111
  • [29] Tamoxifen resistance in a breast cancer xenograft model coincides with a switch from an ER+/PgR+ to an ER+/PgR- phenotype accompanied by EGFR/HER2 activation
    Massarweh, S
    Osborne, CK
    Wakeling, AE
    Schiff, R
    BREAST CANCER RESEARCH AND TREATMENT, 2004, 88 : S18 - S18
  • [30] Predicting benefit from HER2-targeted therapies in patients with ER+/HER2+breast cancer
    Turnbull, A. K.
    Webber, V.
    McStay, D.
    Arthur, L.
    Martinez-Perez, C.
    Fernando, A.
    Renshaw, L.
    Keys, J.
    Clarke, R.
    Sims, A. H.
    Dixon, J. M.
    CANCER RESEARCH, 2019, 79 (04)
12345